# US 2014/0154717 A1 · Method for detecting cancer cell using fluorescently labeled l-glucose derivative, and cancer cell-imaging agent comprising fluorescently labeled l-glucose derivative > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0154717 A1 - Document ID: US20140154717A1 - Status: Published application - Kind: A1 - Application number: 14/007,105 - Filed: 2012-03-29 - Published: 2014-06-05 - Earliest claimed: 2011-03-31 - Assignees: Hirosaki University; Peptide Institute, Inc.; Riken - Inventors: Katsuya Yamada; Hirotaka Onoe; Tadashi Teshima; Toshihiro Yamamoto - Web page: https://patentgrep.com/patent/US20140154717A1 ## CPC - G01N 33/5091: {for testing the pathological state of an organism} - A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)} - A61K 49/0054: {Macromolecular compounds, i.e. oligomers, polymers, dendrimers} - G01N 21/6428: {Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53)} - G01N 33/575: for cancer - G01N 33/582: {with fluorescent label} - G01N 2800/7028: Cancer - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The purpose of the present invention is to provide a method for highly accurately detecting a cancer cell. The method of the present invention is characterized by comprising imaging with the use of a fluorescently labeled L-glucose derivative. By using the method and imaging agent according to the present invention, a high contrast between a cancer cell and a normal cell can be obtained compared with the case that imaging is conducted with the use of a fluorescently labeled D-glucose derivative. According to this method, moreover, no fasting is needed for the determination. Thus, the imaging can be quickly carried out without imposing a burden on a patient. ## Claims ### Claim 1 A method of detecting cancer cells or suspected cells, comprising the following steps: (a) a step of bringing a composition containing an L-glucose derivative having a 7-nitrobenz-2-oxa-1,3-diazole group or its derivative as a fluorescent molecular group in the molecule into contact with a target cell, and (b) a step of detecting the L-glucose derivative present in the target cell. ### Claim 2 (depends on 1) The detection method according to claim 1, wherein the L-glucose derivative is one obtained by linking a 7-nitrobenz-2-oxa-1,3-diazole group or its derivative to the 2-position, 4-position or 6-position of L-glucose or L-glucose in which a hydroxyl group is substituted by an amino group and/or a fluorine atom. ### Claim 3 (depends on 2) The detection method according to claim 2, wherein the position is the 2-position. ### Claim 4 (depends on 3) The detection method according to claim 3, wherein the above-described L-glucose derivative is 2-[N-(7-nitrobenz-2-oxa-1,3-diazole-4-yl)amino]-2-deoxy-L-glucose. ### Claim 5 (depends on 1) The detection method according to claim 1, wherein detection in the step (b) is conducted by imaging the target cell. ### Claim 6 (depends on 1) The detection method according to claim 1, wherein the composition in the step (a) further contains an L-glucose derivative having sulforhodamine in the molecule, and the step (b) is a step of detecting either or both of L-glucose derivatives present in the target cell. ### Claim 7 (depends on 6) The detection method according to claim 6, wherein the composition contains 2-[N-(7-nitrobenz-2-oxa-1,3-diazole-4-yl)amino]-2-deoxy-L-glucose and 2-amino-2-deoxy-L-glucose having sulforhodamine 101 or sulforhodamine B at the 2-position by way of sulfonamide bond. ### Claim 8 (depends on 6) The detection method according to claim 6, wherein detection in the step (b) is conducted by using a temporal change in the fluorescent color tone of the imaged cell as an index. ### Claim 9 (depends on 6) The detection method according to claim 6, further comprising the following step: (c) a step of determining whether the target cell is a cancer cell or a suspected cell or a degraded cell or not, according to the change in the fluorescent color tone. ### Claim 10 (depends on 9) The detection method according to claim 9, wherein the L-glucose derivatives contained in the composition are 2-[N-(7-nitrobenz-2-oxa-1,3-diazole-4-yl)amino]-2-deoxy-L-glucose and 2-amino-2-deoxy-L-glucose having sulforhodamine 101 or sulforhodamine B at the 2-position by way of sulfonamide bond. ### Claim 11 (depends on 4) The detection method according to claim 4, wherein the L-glucose derivative is a radiolabeled L-glucose derivative selected from the group consisting of 6-[18F]-2-[N-(7-nitrobenz-2-oxa-1,3-diazole-4-yl)amino]-2-deoxy-L-glucose and 4-[18F]-2-[N-(7-nitrobenz-2-oxa-1,3-diazole-4-yl)amino]-2-deoxy-L-glucose, and the step of detecting the L-glucose derivative present in the target cell comprises at least PET imaging. ### Claim 12 (depends on 4) The detection method according to claim 4, wherein the composition in the step (a) further contains a fluorescently labeled D-glucose derivative having a fluorescent chromophore group in the molecule. ### Claim 13 An imaging agent for imaging a target cell by uptake of a fluorescently labeled L-glucose derivative into the target cell, wherein the agent contains an L-glucose derivative having a 7-nitrobenz-2-oxa-1,3-diazole group or its derivative as a fluorescent molecular group in the molecule. ### Claim 14 (depends on 13) The imaging agent according to claim 13 for detecting cancer cells or suspected cells. ### Claim 15 (depends on 14) The imaging agent according to claim 14, wherein the L-glucose derivative is one obtained by linking a 7-nitrobenz-2-oxa-1,3-diazole group or its derivative to the 2-position, 4-position or 6-position of L-glucose or L-glucose in which a hydroxyl group is substituted by an amino group and/or a fluorine atom. ### Claim 16 (depends on 15) The imaging agent according to claim 15, wherein the position is the 2-position. ### Claim 17 (depends on 16) The imaging agent according to claim 16, wherein the L-glucose derivative is 2-[N-(7-nitrobenz-2-oxa-1,3-diazole-4-yl)amino]-2-deoxy-L-glucose. ### Claim 18 (depends on 14) The imaging agent according to claim 14, wherein the imaging agent further contains an L-glucose derivative having sulforhodamine in the molecule. ### Claim 19 (depends on 18) The imaging agent according to claim 18, wherein the L-glucose derivative having sulforhodamine in the molecule is 2 amino-2-deoxy-L-glucose having sulforhodamine 101 or sulforhodamine B at the 2-position by way of sulfonamide bond. ### Claim 20 (depends on 17) The imaging agent according to claim 17, wherein the L-glucose derivative is a radiolabeled L-glucose derivative. ### Claim 21 (depends on 17) The imaging agent according to claim 17, further containing a fluorescently labeled D-glucose derivative having a fluorescent chromophore group in the molecule. ### Claim 22 (depends on 17) A kit for detecting cancer cells or suspected cells, comprising the imaging agent according to claim 17. ### Claim 23 (depends on 1) A method of diagnosing that a subject from which the target cell is derived is under cancerous or precancerous condition, comprising detection of cancer cells or suspected cells using the detection method according to claim 1.